MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-16-2026
Atara Biotherapeutics Cash and Cash Equivalents 2011-2026 | ATRA
Annual Cash and Cash Equivalents Atara Biotherapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 8.48 M | 25 M | 25.8 M | 92.9 M | 106 M | 202 M | 74.3 M | 60.7 M | 79.2 M | 48 M | 23.7 M | 21.9 M | 51.6 M | 4.21 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 202 M | 4.21 M | 58.8 M |
Quarterly Cash and Cash Equivalents Atara Biotherapeutics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5.74 M | 16.9 M | 13.8 M | 25 M | 46.6 M | 31.5 M | 35.2 M | 25.8 M | 64.9 M | 46 M | 48.9 M | 92.9 M | 66.5 M | 72 M | 103 M | 106 M | 115 M | 125 M | 151 M | 202 M | 200 M | 200 M | 200 M | 74.3 M | 74.3 M | 74.3 M | 74.3 M | 60.7 M | 60.7 M | 60.7 M | 60.7 M | 79.2 M | 79.2 M | 79.2 M | 79.2 M | 48 M | 48 M | 48 M | 48 M | 23.7 M | 23.7 M | 23.7 M | 23.7 M | 21.9 M | 21.9 M | 21.9 M | 21.9 M | 51.6 M | 51.6 M | - | - | 4.21 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 202 M | 4.21 M | 66.7 M |
Cash and Cash Equivalents of other stocks in the Biotechnology industry
| Issuer | Cash and Cash Equivalents | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Burford Capital Limited
BUR
|
322 M | $ 4.81 | 2.02 % | $ 761 M |  Britain |
 |
Cabaletta Bio
CABA
|
83 M | $ 3.37 | 3.45 % | $ 339 M |  USA |
 |
MorphoSys AG
MOR
|
158 M | - | 2.43 % | $ 254 M |  Germany |
 |
Can-Fite BioPharma Ltd.
CANF
|
8.27 M | $ 3.2 | 4.75 % | $ 5.27 M |  Israel |
 |
Acorda Therapeutics
ACOR
|
30 M | - | -24.86 % | $ 820 K | USA |
 |
Adverum Biotechnologies
ADVM
|
60.7 M | - | - | $ 86.2 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
1.66 B | $ 334.86 | -1.34 % | $ 43.9 B | USA |
 |
I-Mab
IMAB
|
4.76 B | - | - | $ 866 M |  China |
 |
Alterity Therapeutics Limited
ATHE
|
34.8 M | $ 3.73 | 3.04 % | $ 8.97 B |  Australia |
 |
AlloVir
ALVR
|
98.1 M | - | 4.14 % | $ 49.1 M | USA |
 |
Genfit SA
GNFT
|
81.8 M | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
5.57 M | - | -13.47 % | $ 169 M | France |
 |
Aligos Therapeutics
ALGS
|
18.3 M | $ 7.36 | -15.79 % | $ 72.8 M | USA |
 |
Esperion Therapeutics
ESPR
|
168 M | $ 2.08 | 1.22 % | $ 432 M | USA |
 |
Evogene Ltd.
EVGN
|
13 M | $ 0.86 | 4.76 % | $ 27.9 M | Israel |
 |
Allakos
ALLK
|
66.4 M | - | - | $ 28.6 M | USA |
 |
Forte Biosciences
FBRX
|
77 M | $ 31.11 | -4.04 % | $ 403 M | USA |
|
Applied Molecular Transport
AMTI
|
61.1 M | - | - | $ 10.1 M | USA |
 |
Midatech Pharma plc
MTP
|
8.53 M | - | -18.52 % | $ 27.3 M | Britain |
 |
Applied Therapeutics
APLT
|
49.9 M | - | - | $ 8.42 M | USA |
 |
Aptinyx
APTX
|
56.2 M | - | -39.0 % | $ 4.57 M | USA |
 |
Aravive
ARAV
|
53.7 M | - | -13.39 % | $ 1.45 M | USA |
 |
Galapagos NV
GLPG
|
87.9 M | $ 29.11 | 0.8 % | $ 2.69 B |  Belgium |
 |
Genmab A/S
GMAB
|
3.55 B | $ 29.26 | 0.67 % | $ 18.8 B |  Danmark |
 |
GT Biopharma
GTBP
|
6.81 M | $ 0.38 | -1.83 % | $ 2.1 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
170 M | $ 21.69 | 1.45 % | $ 1.01 B | USA |
 |
Harmony Biosciences Holdings
HRMY
|
753 M | $ 29.22 | -0.24 % | $ 1.68 B | USA |
 |
BioNTech SE
BNTX
|
7.68 B | $ 99.83 | 1.44 % | $ 27.2 B | Germany |
 |
Advaxis
ADXS
|
4.88 M | - | -9.65 % | $ 45.9 M | USA |
 |
ImmuCell Corporation
ICCC
|
3.81 M | $ 7.64 | -1.18 % | $ 69 M | USA |
 |
Aeterna Zentaris
AEZS
|
7.31 M | - | 5.93 % | $ 314 M |  Canada |
 |
InflaRx N.V.
IFRX
|
16 M | $ 1.21 | 6.14 % | $ 152 M | Germany |
 |
AgeX Therapeutics
AGE
|
3.06 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
85.7 M | - | - | $ 1.01 B | USA |
 |
Akebia Therapeutics
AKBA
|
185 M | $ 1.54 | -1.23 % | $ 396 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
46.4 M | - | - | $ 26.5 M | USA |
|
Immatics N.V.
IMTX
|
208 M | $ 10.97 | 0.18 % | $ 690 M | Germany |
 |
Aquestive Therapeutics
AQST
|
121 M | $ 4.19 | 1.07 % | $ 448 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
42.9 M | $ 24.26 | -3.31 % | $ 3.09 B | USA |
 |
Incyte Corporation
INCY
|
3.1 B | $ 97.7 | 0.01 % | $ 19.1 B | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
29 K | - | -2.5 % | $ 5.88 M | USA |
 |
AIkido Pharma
AIKI
|
34 M | - | 1.93 % | $ 17.4 M | USA |
 |
Innate Pharma S.A.
IPHA
|
28.1 M | $ 1.66 | 1.57 % | $ 235 M | France |
 |
BioDelivery Sciences International
BDSI
|
112 M | - | -4.8 % | $ 255 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
104 M | $ 1.48 | -0.34 % | $ 394 M | Britain |
 |
Aptose Biosciences
APTO
|
935 K | - | -45.71 % | $ 1.2 M | Canada |
 |
BeiGene, Ltd.
BGNE
|
4.55 B | - | 0.49 % | $ 251 B |  Cayman-islands |